Bosutinib’s domestic market price and medical insurance reimbursement status

Bosutinib has not yet been approved for marketing in China. If patients want to use the drug, they must purchase it through regular overseas channels. In mainland China, bosutinib is not included in the national medical insurance catalog and therefore cannot be reimbursed through medical insurance. Patients must bear all costs themselves. However, as China attaches greater importance to leukemia treatment, bosutinib is expected to be included in the medical insurance catalog in the future, which will significantly reduce the financial burden on patients.

The price of bosutinib varies by manufacturer and region. The selling price of the original drug in the European market is relatively high, with each box (500mg*28tablets) costing about more than 30,000 yuan. In comparison, the imitation version produced by India's Mylan (Mylan) is more affordable, with each box selling for about more than 1,000 yuan. This price difference requires patients to comprehensively consider the reliability of drug sources and therapeutic effects when making choices.

At present, bosutinib has not been approved for marketing in China, so it is not in the national medical insurance directory and cannot be reimbursed through medical insurance. If the patient needs to use this drug, he or she must bear all costs. However, some areas may provide partial reimbursement through critical illness insurance. Patients can consult the local medical insurance department or medical institution to find out whether there are relevant policy supports.

When patients are considering the use of bosutinib, they should first consult their primary care physician to understand whether the drug is suitable for their condition. When purchasing medicines, it is recommended to choose formal channels to ensure the reliability of the source of medicines and avoid purchasing fake and shoddy products. In addition, patients can also pay attention to some charitable assistance projects or special medical insurance drug policies. Some areas may provide partial reimbursement through critical illness insurance. With the increasing emphasis on leukemia treatment in China, bosutinib is expected to be included in the medical insurance catalog in the future, which will significantly reduce the financial burden on patients.

Reference materials:https://www.drugs.com/